October 31, 2016

Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder

Articles in Press
Atopic dermatitis comorbidities extend well beyond the march to allergic conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic immune activation. In reviewing atopic dermatitis comorbidities, Councilors of the International Eczema Council found a strong pattern of immune activation in peripheral blood and the propensity to both skin and systemic infections.

October 27, 2016

Specific Antibodies for the Detection of Alternaria Allergens and the Identification of Cross-Reactive Antigens in Other Fungi

Twaroch T.E.a · Curin M.a · Sterflinger K.b · Focke-Tejkl M.a · Swoboda I.a ·Valenta R.a
aChristian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, and bDepartment for Biotechnology, University of Natural Resources and Applied Life Sciences, Vienna, Austria

Abstract:
Background: The mould Alternaria alternata is an important source of respiratory allergens. A. alternata extracts show great variations regarding allergenic potency. The aim of this study was to generate antibody probes specific for important Alternaria allergens and to use them to study allergen expression, depending on different culture conditions, as well as to search for cross-reactive allergens in other mould species. Methods: Synthetic peptides from antigenic regions of A. alternataallergens (Alt a 1, Alt a 2, Alt a 3, Alt a 6 and Alt a 8) were used to raise highly specific rabbit antibodies.

Effect of educational and electronic medical record interventions on food allergy management

Logo of allapSearchwww.oceansidepubl.com
Allergy and Asthma Proceedings
. 2016 Sep-Oct; 37(5): 404–408.
PMCID: PMC5013233
Ari Zelig, M.D.,1 Ilana Harwayne-Gidansky, M.D.,2 Allison Gault, M.D.,3 and Julie Wang, M.D.corresponding author3

Abstract
Background:
The growing prevalence of food allergies indicates a responsibility among primary care providers to ensure that their patients receive accurate diagnosis and management.

Late‐Onset Asthma Predicts Cardiovascular Disease Events: The Wisconsin Sleep Cohort

  •  Am Heart Assoc. 5: e003448
    doi: 10.1161/JAHA.116.003448
  • Original Research - Epidemiology
  1. James H. Stein, MD, FAHA*,1
+Author Affiliations
  1. 1Division of Cardiovascular MedicineDepartment of MedicineUniversity of Wisconsin School of Medicine and Public HealthMadisonWI
  2. 2Department of Population HealthUniversity of Wisconsin School of Medicine and Public HealthMadisonWI
Abstract
Background Asthma is a heterogeneous syndrome with different clinical subtypes that is associated with an increased risk for cardiovascular disease (CVD). We hypothesized that the late‐onset subtype of asthma is associated with a higher risk of incident CVD.

October 26, 2016

Urine metabolome profiling of immune-mediated inflammatory diseases

BMC Medicine

 
OPEN ACCESS
 
OPEN PEER REVIEW

  • Arnald Alonso,
  • Antonio JuliàEmail authorView ORCID ID profile,
  • Maria Vinaixa,
  • Eugeni Domènech,
  • Antonio Fernández-Nebro,
  • Juan D. Cañete,
  • Carlos Ferrándiz,
  • Jesús Tornero,
  • Javier P. Gisbert,
  • Pilar Nos,
  • Ana Gutiérrez Casbas,
  • Lluís Puig,
  • Isidoro González-Álvaro,
  • José A. Pinto-Tasende,
  • Ricardo Blanco,
  • Miguel A. Rodríguez,
  • Antoni Beltran,
  • Xavier Correig,
  • Sara MarsalEmail author and
  • for the IMID Consortium
Abstract
Background
Immune-mediated inflammatory diseases (IMIDs) are a group of complex and prevalent diseases where disease diagnostic and activity monitoring is highly challenging. The determination of the metabolite profiles of biological samples is becoming a powerful approach to identify new biomarkers of clinical utility. In order to identify new metabolite biomarkers of diagnosis and disease activity, we have performed the first large-scale profiling of the urine metabolome of the six most prevalent IMIDs: rheumatoid arthritis, psoriatic arthritis, psoriasis, systemic lupus erythematosus, Crohn’s disease, and ulcerative colitis.

Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope

Open Access  Review Article 
  • Arathi Kizhedath
  • Simon Wilkinson
  • Jarka Glassey
Abstract
Biopharmaceuticals, monoclonal antibody (mAb)-based therapeutics in particular, have positively impacted millions of lives. MAbs and related therapeutics are highly desirable from a biopharmaceutical perspective as they are highly target specific and well tolerated within the human system. Nevertheless, several mAbs have been discontinued or withdrawn based either on their inability to demonstrate efficacy and/or due to adverse effects.

October 25, 2016

Mast cell desensitization inhibits calcium flux and aberrantly remodels actin

J Clin Invest. 2016. doi:10.1172/JCI87492.
View: Text | PDF

First published September 26, 2016 - 
Abstract
Rush desensitization (DS) is a widely used and effective clinical strategy for the rapid inhibition of IgE-mediated anaphylactic responses. However, the cellular targets and underlying mechanisms behind this process remain unclear. Recent studies have implicated mast cells (MCs) as the primary target cells for DS. Here, we developed a murine model of passive anaphylaxis with demonstrated MC involvement and an in vitro assay to evaluate the effect of DS on MCs.

October 24, 2016

Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

Logo of dibGuide for AuthorsAboutExplore this JournalData in Brief
. 2016 Dec; 9: 199–205.
Published online 2016 Aug 29. doi:  10.1016/j.dib.2016.08.039
PMCID: PMC5021787
Abstract
This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients.